Madina Zhalbinova

Mrs. Madina Zhalbinova

Nazarbayev University, Nur-Sultan, Astana, Kazakhstan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Genes
Verified
Journal Article
Open access
PDF file
AAAyan Abdrakhmanov
Ayan Abdrakhmanov
AAAinur Rakhmetulovna Akilzhanova
Ainur Rakhmetulovna Akilzhanova
ASAizhan Shaimerdinova
Aizhan Shaimerdinova
Madina ZhalbinovaMadina Zhalbinova
Madina Zhalbinova
GTGulnara Tuyakova
Gulnara Tuyakova
MBMakhabbat S Bekbossynova
Makhabbat S Bekbossynova
Nowadays, direct oral anticoagulants (DOACs) are the first-line anticoagulant strategy in patients with non-valvular atrial fibrillation (NVAF). We aimed to identify the influence of polymorphisms of the genes encoding P-glycoprotein (ABCB1) and carboxylesterase 1 (CES1) on the variability of plasma concentrations of DOACs in Kazakhstani patients with NVAF. We analyzed polymorphisms rs4148738, rs1045642, rs2032582 and rs1128503 in ABCB1 and rs8192935, rs2244613 and rs71647871 CES1 genes and measured the plasma concentrations of dabigatran/apixaban and biochemical parameters in 150 Kazakhstani NVAF patients. Polymorphism rs8192935 in the CES1 gene (p = 0.04), BMI (p = 0.01) and APTT level (p = 0.01) were statistically significant independent factors of trough plasma concentration of dabigatran. In contrast, polymorphisms rs4148738, rs1045642, rs2032582 and rs1128503 in ABCB1 and rs8192935, rs2244613 and rs71647871 CES1 genes did not show significant influence on plasma concentrations of dabigatran/apixaban drugs (p > 0.05). Patients with GG genotype (138.8 ± 100.1 ng/mL) had higher peak plasma concentration of dabigatran than with AA genotype (100.9 ± 59.6 ng/mL) and AG genotype (98.7 ± 72.3 ng/mL) (Kruskal–Wallis test, p = 0.25). Thus, CES1 rs8192935 is significantly associated with plasma concentrations of dabigatran in Kazakhstani NVAF patients (p < 0.05). The level of the plasma concentration shows that biotransformation of the dabigatran processed faster in individual carriers of GG genotype rs8192935 in the CES1 gene than with AA genotype.

Verified
Journal Article
Open access
PDF file
Madina ZhalbinovaMadina Zhalbinova
Madina Zhalbinova
SRSaule Rakhimova
Saule Rakhimova
UKUlan Kozhamkulov
Ulan Kozhamkulov
GAGulbanu A. Akilzhanova
Gulbanu A. Akilzhanova
GKGalina K. Kaussova
Galina K. Kaussova
AAAinur Rakhmetulovna Akilzhanova
Ainur Rakhmetulovna Akilzhanova
The left ventricular assist device (LVAD) is one of the alternative treatments for heart failure (HF) patients. However, LVAD support is followed by thrombosis, and bleeding complications which are caused by high non-physiologic shear stress and antithrombotic/anticoagulant therapy. A high risk of complications occurs in the presence of the genotype polymorphisms which are involved in the coagulation system, hemostasis function and in the metabolism of the therapy. The aim of the study was to investigate the influence of single-nucleotide polymorphisms (SNP) in HF patients with LVAD complications. We analyzed 21 SNPs in HF patients (n = 98) with/without complications, and healthy controls (n = 95). SNPs rs9934438; rs9923231 in VKORC1, rs5918 in ITGB3 and rs2070959 in UGT1A6 demonstrated significant association with HF patients’ complications (OR (95% CI): 3.96 (1.42–11.02), p = 0.0057), (OR (95% CI): 3.55 (1.28–9.86), p = 0.011), (OR (95% CI): 5.37 (1.79–16.16), p = 0.0056) and OR (95% CI): 4.40 (1.06–18.20), p = 0.044]. Genotype polymorphisms could help to predict complications at pre- and post-LVAD implantation period, which will reduce mortality rate. Our research showed that patients can receive treatment with warfarin and aspirin with a personalized dosage and LVAD complications can be predicted by reference to their genotype polymorphisms in VKORC1, ITGB3 and UGT1A6 genes.

22 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Madina ZhalbinovaMadina Zhalbinova
Madina Zhalbinova
SRSaule Rakhimova
Saule Rakhimova
UKUlan Kozhamkulov
Ulan Kozhamkulov
GAGulbanu A. Akilzhanova
Gulbanu A. Akilzhanova
ACAssel A. Chinybayeva
Assel A. Chinybayeva
AAAinur Rakhmetulovna Akilzhanova
Ainur Rakhmetulovna Akilzhanova
Left ventricular assist device (LVAD) implantation is one of the mechanical circulatory support (MCS) treatments for advanced heart failure (HF) patients. MCS has emerged as a lifesaving therapy that improves patients’ quality of life. However, MCS remains limited by a paradoxical coagulopathy accompanied by thrombosis and bleeding. The mechanisms of MCS thrombosis are increasingly being defined, but MCS-related bleeding, which is related to shear-mediated alteration of platelet function, remains poorly understood. Complications might develop due to the high non-physiological shear stress in the device and as a consequence of individual variability in response to the antithrombotic therapy. Thromboelastography (TEG) and genotyping of gene polymorphisms that are involved in the coagulation cascade and in the metabolism of the antithrombotic therapy might be valuable sources of information for the reduction of complication development. The aim of the study was to identify genetic factors related to the development of device complications according to the implanted LVAD type. We compared the clinical and genetic data of HF patients (n = 98) with/without complications with three types of implanted devices: HeartWare HVAD (HW), HeartMate II (HMII), and HeartMate 3 (HM3). rs9923231 in VKORC1 (95%CI −6.28–0.22, p = 0.04) and rs5918 in ITGB3 genes (95%CI 0.003–4.36, p = 0.05) showed significant association with the TEG coagulation index parameter, which identified hyper- and hypo-coagulation states. The wild genotype of rs5918 in the ITGB3 gene prevailed in patients implanted with HM3 devices, which developed fewer complications than with HMII (p = 0.04). Individual genetic information could be useful in the management of patients with HF and the implantation of MCS to reduce the development of complications.

Verified
Journal Article
Open access
PDF file
ACAyaulym Chamoieva
Ayaulym Chamoieva
ZMZhanel Mirmanova
Zhanel Mirmanova
Madina ZhalbinovaMadina Zhalbinova
Madina Zhalbinova
SRSaule Rakhimova
Saule Rakhimova
ADAsset Daniyarov
Asset Daniyarov
AAAinur Rakhmetulovna Akilzhanova
Ainur Rakhmetulovna Akilzhanova
Familial hypercholesterolemia is an autosomal hereditary disease defined by an increased level of low-density lipoprotein cholesterol (LDL-C), which predisposes significant risks for premature cardiovascular disorders. We present a family trio study: proband, a 13-year-old Kazakh girl with homozygous familial hypercholesterolemia (HoFH) and her parents. HoFH is much more rare and severe than a heterozygous form of the disorder. HoFH patients generally present with LDL-C levels exceeding 13 mmol/L, resulting in early and life-threatening cardiovascular events within the first decades of life. In cases of neglected treatment, young patients have a risk of death from coronary diseases before the age of 30. The aim of this research was to identify genetic mutations in the affected patient and her parents. Genetic testing was necessary due to highly elevated LDL-C levels and the presence of multiple xanthomas. Targeted next-generation sequencing (NGS) was performed in this study using the Illumina TruSight cardio panel, which targets 174 genes related to cardiac disorders. The girl was diagnosed with HoFH based on the results of genetic testing. A biallelic mutation was observed in exon 3 of the low-density lipoprotein receptor (LDLR): c. 295 G>A (p.Glu99Lys). Sanger sequencing confirmed that the mutant gene was inherited from both parents. After confirming the genetic diagnosis of HoFH, the patient was treated with LDL apheresis and statins. This case report is the first study of HoFH in a pediatric patient from the Central Asian region. Globally, it emphasizes the need for increased clinical awareness among healthcare providers, as early detection and intervention are important for improving outcomes, particularly in pediatric patients with this rare genetic disorder.

8 February 2024
Verified
Book Chapter
Closed access
PDF file
VKVitalii Kupaev
Vitalii Kupaev
Madina ZhalbinovaMadina Zhalbinova
Madina Zhalbinova
WZWei Zhang
Wei Zhang

28 February 2023 in Наука и здравоохранение
Verified
Journal Article
Open access
Madina ZhalbinovaMadina Zhalbinova
Madina Zhalbinova
SRSaule Rakhimova
Saule Rakhimova
ASAndosova S.A.
Andosova S.A.
AGAkilzhanova G.A.
Akilzhanova G.A.
BMBekbosynova M.S.
Bekbosynova M.S.
AAAinur Rakhmetulovna Akilzhanova
Ainur Rakhmetulovna Akilzhanova
Relevance. Left ventricular assist device (LVAD) is an alternative treatment for heart failure (HF) patients which improves patient’s quality of life at their end-stage. Despite to the improvement LVAD is beleaguered with thrombosis/bleeding complications in 70% of HF patients after implantation. An anticoagulant treatment of warfarin is usually prescribed to reduce thrombosis complications. However, due to the incorrect dosage of the treatment thrombosis/ bleeding complications still happen. Warfarin dose could be identified by genetic variants of vitamin K-epoxide reductase complex (VKORC1) and the cytochrome P450-2C9 (CYP2C9) which account for 50% of dose variability. Aim. The aim of our investigation is to identify variability of warfarin dose according to the genotype polymorphisms of genes and their difference from the clinical dosage in HF patients. Materials and methods. The case series study included 98 HF patients (without complications – 74 patients, with complications – 24 patients) with prescribed warfarin treatment after device implantation. Clinical warfarin dosage difference was identified between genotype polymorphisms of rs9923231, rs9934438 in VKORC1 gene. Furthermore, warfarin dosage was calculated according to the genetic test results and compared with clinical dosage. Results. Warfarin dosage according to the clinical protocol between three genotypes of polymorphisms in VKORC1gene showed significant difference. HF patients were prescribed with higher warfarin dosage with wild type genotype polymorphism of rs9934438 in VKORC1 gene than with mutant genotype < 2.5mg (3.88 ± 1.25 vs. 2.44 ± 0.81, p = 0.00005). Conclusion. Genotype-guided warfarin dosing may estimate accurate dose and potentially improve outcomes in LVAD patients. Введение. Вспомогательное механическое устройство левого желудочка (Left ventricular assist device, LVAD) является альтернативным методом лечения пациентов с сердечной недостаточностью (СН), которое улучшает качество жизни пациентов на терминальной стадии. Несмотря на улучшение, LVAD сопровождается тромбозами/кровотечениями у 70% пациентов с СН после имплантации. Антикоагулянтное лечение варфарином обычно назначают для уменьшения осложнений тромбоза. Однако из-за неправильной дозировки лечения осложнения тромбоза/кровотечения все же случаются. Дозу варфарина можно определить по генетическим вариантам комплекса витамин К-эпоксидредуктазы (VKORC1) и цитохрома P450-2C9 (CYP2C9), которые влияет на вариабельности дозы на 50%. Цель. Целью нашего исследования является выявление вариабельности дозы варфарина в зависимости от генетических полиморфизмов генов и их отличия от клинической дозы у больных СН. Материалы и методы. В исследование серии случаев включены 98 пациентов с СН (без осложнений – 74 пациента, с осложнениями – 24 пациента), получавших лечение варфарином после имплантации устройства. Выявлена клиническая разница в дозировке варфарина между полиморфизмами генотипов rs9923231, rs9934438 гена VKORC1. Кроме того, дозировка варфарина рассчитывалась по результатам генетического теста и сравнивалась с клинической дозировкой. Результаты. Дозировка варфарина согласно клиническому протоколу между тремя генотипами полиморфизмов гена VKORC1 показала значительную разницу. Пациентам с СН назначали более высокие дозы варфарина при диком типе полиморфизма rs9934438 гена VKORC1, чем при мутантном генотипе <2,5 мг (3,88 ± 1,25 против 2,44 ± 0,81, p = 0,00005). Выводы. Дозирование варфарина с учетом генотипа может дать точную оценку дозы и потенциально улучшить исходы у пациентов с LVAD. Өзектілігі. Сол жақ қарыншаның көмекші механикалық құрылғысы (Left ventricular assist device, LVAD) жүрек жеткіліксіздігі (ЖЖ) бар науқастарға арналған балама емдеу әдісі болып табылады, ол соңғы сатыдағы пациенттердің өмір сапасын жақсартады. Жақсарғанына қарамастан, 70% ЖЖ пациенттерінде тромбоз/ қан кету асқынулары пайда болады LVAD имплантациясынан кейін. Тромбоздың асқынуын азайту үшін антикоагулянттық емдеу варфаринмен әдетте тағайындалады. Дегенмен, тромбоз/қан кету асқынулары емдеудің дұрыс емес дозасынан туындайды. Дозаның өзгергіштігіне 50%-ға...